Edition:
India

Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

37.91USD
9:46pm IST
Change (% chg)

$0.05 (+0.13%)
Prev Close
$37.86
Open
$37.82
Day's High
$38.15
Day's Low
$37.36
Volume
49,960
Avg. Vol
88,420
52-wk High
$41.80
52-wk Low
$14.00

Chart for

About

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the... (more)

Overall

Beta: --
Market Cap(Mil.): $722.67
Shares Outstanding(Mil.): 27.78
Dividend: --
Yield (%): --

Financials

BRIEF-Audentes Announces Positive Interim Data From First Dose Cohort Of Aspiro

* AUDENTES ANNOUNCES POSITIVE INTERIM DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY

04 Jan 2018

BRIEF-Audentes Therapeutics Q3 ‍loss per share $ 0.88​

* Audentes Therapeutics reports third quarter 2017 financial results and provides corporate update

15 Nov 2017

BRIEF-Audentes Therapeutics to release Q3 financial results Nov. 14

* Audentes Therapeutics to release third quarter 2017 financial results and provide corporate update on Tuesday, November 14, 2017 Source text for Eikon: Further company coverage:

07 Nov 2017

BRIEF-Audentes Therapeutics gets fast track designation for its muscle disorder drug

* Audentes Therapeutics announces rare pediatric disease and fast track designations for AT132 for the treatment of x-linked myotubular myopathy

27 Sep 2017

BRIEF-Audentes Therapeutics commences dosing of first patient in phase 1/2 trial of AT132 for the treatment of x-linked myotubular myopathy

* Audentes Therapeutics announces dosing of first patient in ASPIRO, a phase 1/2 clinical trial of AT132 for the treatment of X-linked myotubular myopathy

21 Sep 2017

BRIEF-Audentes Therapeutics files for mixed shelf offering of up to $250 mln‍​

* Audentes Therapeutics Inc files for mixed shelf offering of up to $250 million - sec filing‍​ Source text: (http://bit.ly/2fqe6ME) Further company coverage:

09 Aug 2017

Competitors

  Price Chg
Amicus Therapeutics, Inc. (FOLD.OQ) $16.04 +0.14
Sanofi SA (SASY.PA) €69.89 -3.06

Earnings vs. Estimates